Good outlook for Novozymes after eventful 2013

Published: 27-Jan-2014
Ingredients Finance

Strong increase in sales of products for the manufacture of pharmaceuticals


Danish enzymes producer Novozymes expects strong sales and earnings in 2014, after what Peder Holk Nielsen, President and CEO, described as an 'eventful 2013'.

Organic sales growth in 2013 was up 7% to DKK11.7bn (US$2.14bn), EBIT grew by 6% to DKK2.9bn and net profit by 9% to DKK2.2bn.

Sales to the Technical & Pharma Industries increased by 7% to DKK757m, driven by a strong increase in sales for the manufacture of pharmaceutical products, particularly in Europe, the Middle East and Africa.

Holk Nielsen said: 'We delivered a good finish to the year and ended at the high end of our guided ranges for sales growth and above that for earnings. The outlook for 2014 is positive. We expect that our diversified growth platform will enable us to deliver good sales and EBIT growth.'

  • Companies:
  • Novozymes
See more

You may also like

Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Read more
Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits

Trending Articles

  1. Rousselot Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global customer-base, we deliver advanced ingredient solutions that enable innovation, excite today’s consumers, and contribute to public health. Rousselot is a brand of Darling Ingredients<br><br><sup>*Global Gelatin Market Insights Forecast to 2026, Calibre Research, 2020</sup>
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  5. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Finance

Novo companies announce enzyme collaboration for biopharmaceuticals

Enzymes used in biopharmaceutical processing make up a small part of the 15bn DKK ($2.3bn) market for specialty enzymes, with yearly expected growth rates in the high-single digits
Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
Finance

Novozymes reports 4% increase in sales in Q1

Biopharma sales rise by 22%
Ingredients

Novozymes’ agreement with GSK brings payback closer

GSK is seeking approval in Europe for diabetes drug Eperzan
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Safe, consistent and sustainable hyaluronic acid

Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Ingredients

Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name

Portfolio will bring together rAlbumin product line with introduction of new brand names Recombumin Alpha and Recombumin Prime
Ingredients

Enzymes cut industrial emissions and resource use

Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
Subscribe now